Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06360354 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
A Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06360354 is a Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers that is actively recruiting participants, run by Amgen. The registered enrollment target is 350 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06360354, a Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG RMC-6236
- DRUG AMG 193
- DRUG Modified FOLFIRINOX
Study Locations (20)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- Translational Research in Oncology US Inc, Trio Central Pharmacy - Los Angeles
- University of California Los Angeles - Santa Monica
Connecticut
- Hartford Hospital - Hartford
- Yale University - New Haven
- Norwalk Hospital - Norwalk
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- Rocky Mountain Cancer Centers - Aurora
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- Norton Cancer Institute - Louisville
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2029-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06360354
The ClinicalTrials.gov registry entry for NCT06360354 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT06360354 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06360354 about?
NCT06360354 is a clinical study titled "A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)". The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastroin...
What is the current status of trial NCT06360354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2024-05-29. Estimated completion is 2029-02-25.
What conditions does trial NCT06360354 study?
This clinical trial studies the following conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers.
What interventions are being tested in trial NCT06360354?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), RMC-6236 (DRUG), AMG 193 (DRUG), Modified FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT06360354?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06360354 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.